Tazan

General characteristics. Structure:

Active agents: a sodium sulfate glycosamine chloride (in terms of a glycosamine sulfate) — 500 mg; chondroitin sodium sulfate - 500 mg;
Excipients: silicon dioxide colloid (aerosil) — 8,5 mg, calcium stearate — 17,0 mg, talc — 51,0 mg, кросповидон (коллидон TsL) — 170,0 mg, povidone low-molecular (polyvinylpirrolidone low-molecular medical 12600+2700) — 86,0 mg, potato starch — 4,5 mg, лудипресс (structure: lactoses monohydrate — 91-95%, povidone — 3-4%, кросповидон — 3-4%) — before obtaining mass of a kernel of 1700 mg;
Structure of a cover: a gipromelloz (oksipropilmetiltsellyuloz) — 27,2 mg, propylene glycol — 2,5 mg, a macrogoal (polyethyleneglycol 4000) — 23,8 mg, titanium dioxide - 16,5 mg.

Pharmacological properties:

Stimulates regeneration of cartilaginous tissue. The glycosamine and chondroitin sulfate take part in synthesis of connecting fabric, promoting prevention of processes of destruction of a cartilage and stimulating fabric regeneration. Introduction of an exogenous glycosamine strengthens development of a cartilaginous matrix and provides nonspecific protection against chemical injury of a cartilage. The glycosamine in the form of sulphatic salt is a predecessor a hexosemine, and sulfate-anion is necessary for synthesis of glikozaminoglikan. Other possible function of a glycosamine is protection of the injured cartilage against the metabolic destruction caused by non-steroidal anti-inflammatory drugs and glucocorticosteroid and also own moderate antiinflammatory action.

Chondroitin sulfate irrespective of whether it is soaked up in an intact form or in the form of separate components, serves as additional substrate for formation of a healthy cartilaginous matrix. Stimulates formation of a gialuronon, synthesis of proteoglycans and collagen like II, and also protects гиалуронон from zymolysis (by suppression of activity of hyaluronidase) and from the damaging action of free radicals; maintains viscosity of synovial fluid, stimulates cartilage reparation mechanisms. At treatment of an osteoarthrosis facilitates symptoms of a disease and reduces the need for non-steroidal anti-inflammatory drugs
 
With care of Bleeding, tendency to bleeding, diabetes mellitus, bronchial asthma.

Indications to use:

Osteoarthrosis of the I-III St.

Route of administration and doses:

Inside. To adults and children 15 years on 1 tablet 2 times a day within the three first weeks, on 1 tablet once a day within the next weeks and months are more senior.

The steady medical effect is reached at administration of drug not less than 6 months.

Features of use:

At emergence of undesirable effects from digestive tract the dose of drug should be reduced twice, and in the absence of improvement - to cancel drug. In the absence of clinical effect after a medical course on 4 tablets a day within 4 weeks it is necessary to resolve an issue of specification of the diagnosis
 
Vlianiye on ability to driving of motor transport and control of mechanisms: 
Respect for care at control of vehicles and occupations is required by other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

Dysfunction of digestive tract (pain in epigastriums, a meteorism, diarrhea or a lock), dizziness, skin allergic reactions, a headache, an onychalgia and peripheral hypostases, drowsiness, sleeplessness, tachycardia, allergic reactions.

Interaction with other medicines:

Increases absorption of tetracyclines, reduces effect of polysynthetic penicillin and a glycosamine. Drug is compatible to non-steroidal anti-inflammatory drugs and glucocorticosteroid strengthening of effect of anticoagulants, antiagregant, fibrinolitik is possible.

Contraindications:

Hypersensitivity to drug components, children's age up to 18 years, the expressed renal failure.

 
Use at pregnancy At pregnancy and during breastfeeding (lactation) drug is not used.

Overdose:

Symptoms: cases of overdose are unknown.

Treatment: gastric lavage, symptomatic therapy.

Storage conditions:

In the place protected from light, at a temperature not above 25 °C. To store in the places unavailable to children. 
Period of validity 3 years. Not to use after the period of validity specified on packaging.

Issue conditions:

Without recipe

Packaging:

The tablets covered film an obol., 500 mg +500 mg: 30, 60 or 90 pieces.